Abstract：Objective To investigate the clinical efficacy and safety of intravenous thrombolysis bridging stent thrombectomy in the treatment of acute cerebral infarction.Methods 102 patients with acute cerebral infarction caused by intracranial artery occlusion were selected.The control group received intravenous thrombolysis with recombinant human tissue type plasminogen activator（trade name：alteplase）（RT PA）,while the observation group was treated with solitaire AB stent bridging on the basis of RT PA intravenous thrombolysis,The clinical effect,blood vessel recanalization and activities of daily living（ADL）,serological indexes and safety of the two groups were analyzed.Results There was no significant difference in NIHSS and Barthel scores between the two groups before treatment（P>0.05）;After treatment,the NIHSS score of the observation group was lower than that of the control group,Barthel score was higher（P<0.05）;The recanalization rate of the observation group was 70.59%,which was higher than 41.18% of the control group（P<0.05）;There was no significant difference in hs CRP,sICAM-1,IGF-1 and NSE between the two groups before treatment（P>0.05）;After treatment,the levels of hs CRP,sICAM-1 and NSE in the two groups decreased,while IGF-1 increased to a certain extent.The levels of hs CRP,sICAM-1 and NSE in the observation group were lower than those in the control group,while IGF-1 in the observation group was higher than that in the control group,The difference was statistically significant（P<0.05）;There was no significant difference in the total incidence of complications between the two groups（P>0.05）,and there was no significant difference in 90d mortality between the two groups（P>0.05）.Conclusion Compared with single intravenous thrombolytic therapy,intravenous thrombolytic bridging stent can obtain better clinical efficacy in the treatment of acute cerebral infarction,The reduction of nerve injury is conducive to the recovery of nerve function,and the inflammatory reaction is relieved.The incidence of complications and 90 day mortality is less,so it has high application value.
李栋, 马成东, 王书峰. 静脉溶栓桥接支架取栓治疗急性脑梗死的临床疗效及安全性分析[J]. 哈尔滨医药, 2023, 43(3): 4-6.
Li Dong, Ma Chengdong, Wang Shufeng. Clinical Efficacy and Safety Analysis of Intravenous Thrombolysis and Bridging Stent Thrombectomy in the Treatment of Acute Cerebral Infarction. journal1, 2023, 43(3): 4-6.
2023, Vol. 43 
